MetadataShow full item record
AbstractOvarian cancer shows considerable variability in its chemoresponse, however, the prospect of individualized medicine holds high hopes for improving patient survival. The influence of interindividual genomic polymorphisms on drug response (pharmacogenomics) is well established, and a variety of candidate loci in ovarian tumors have been identified, including ERCC1, ABCB1 and p53 variants. Recently pharmacoepigenomic modulators of key genes and pathways, such as promoter methylation (MLH1 and BRCA1 genes) and microRNA regulation (PTEN/AKT and NF-kappaB pathways) have been implicated in ovarian cancer chemoresponse. Epigenomic studies have until now mainly focused on tumor-specific changes, although germ-line epigenetic change may also be of importance. However, assessing the relevance of these potential pharmaco(epi)genomic biomarkers in clinical trials requires well powered studies in homogeneous populations, with independent validation sets, to distinguish real associations from false-positives. In addition, the selection of one gene or locus as having sufficient phenotypic effect to impact on clinical outcome may be an oversimplification. Integrated approaches that identify stable pharmacogenomic and epigenomic patterns and their relationship with expression patterns and gene function will be increasingly necessary.
CitationPaige, A.J.W., Brown, R. (2008) 'Pharmaco(epi)genomics in ovarian cancer' Pharmacogenomics 9 (12):1825-1834
- Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish Randomised Trial in Ovarian Cancer.
- Authors: Marsh S, Paul J, King CR, Gifford G, McLeod HL, Brown R
- Issue date: 2007 Oct 10
- BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group.
- Authors: Alsop K, Fereday S, Meldrum C, deFazio A, Emmanuel C, George J, Dobrovic A, Birrer MJ, Webb PM, Stewart C, Friedlander M, Fox S, Bowtell D, Mitchell G
- Issue date: 2012 Jul 20
- An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer.
- Authors: Dressman HK, Berchuck A, Chan G, Zhai J, Bild A, Sayer R, Cragun J, Clarke J, Whitaker RS, Li L, Gray J, Marks J, Ginsburg GS, Potti A, West M, Nevins JR, Lancaster JM
- Issue date: 2007 Feb 10
- Matrix metalloproteinase pharmacogenomics in non-small-cell lung carcinoma.
- Authors: Chetty C, Rao JS, Lakka SS
- Issue date: 2011 Apr
- Specific copy number alterations associated with docetaxel/carboplatin response in ovarian carcinomas.
- Authors: Osterberg L, Levan K, Partheen K, Delle U, Olsson B, Sundfeldt K, Horvath G
- Issue date: 2010 Nov